Table 1. Characteristics of randomized controlled clinical trials in the meta-analysis.
| Acronym | Design | Treatment arm | Control arm | Concurrent treatment | Number of patients | Disease | Mean age (range, years) | Women (%) | Follow up (months) | Lost tofollow-up (%) | Quality score |
| VISION22 | DB-P | Pegaptanib | Placebo | Verteporfin | 1190 | Neovascular AMD | NA | 696 (58.5) | 12 | 11.5 | 5 |
| MARINA23 | DB-P | Ranibizumab | Placebo | Verteporfin | 716 | Neovascular AMD | 77 (52–95) | 464 (64.8) | 24 | 14.1 | 5 |
| FOCUS24 | SB-P | Ranibizumab | Placebo | Verteporfin | 162 | Neovascular AMD | 74 (50–93) | 86 (53.1) | 24 | 14.8 | 4 |
| ANCHOR25 | DB-P | Ranibizumab | Verteporfin | Laser | 423 | Neovascular AMD | 77 (53–97) | 211 (49.9) | 24 | 22.2 | 5 |
| BOLT26 | SB-P | Bevacizumab | Laser | None | 80 | DME | 64 (40–86) | 25 (31.3) | 12 | 2.5 | 4 |
| ABC Trial27 | DB-P | Bevacizumab | Placebo, verteporfin, pegaptanib | None | 131 | Neovascular AMD | 81 (NA) | 80 (61.1) | 12 | 4.8 | 5 |
| PIER28 | DB-P | Ranibizumab | Placebo | Verteporfin | 184 | Neovascular AMD | 78 (54–94) | 110 (59.8) | 24 | 16.8 | 5 |
| RESOLVE29 | DB-P | Ranibizumab | Placebo | None | 151 | DME | 64 (32–85) | 70 (46.4) | 12 | 12.6 | 5 |
| BRAVO30 | DB-P | Ranibizumab | Placebo | Laser | 397 | BRVO | 66 (26–91) | 185 (46.6) | 12 | 10.3 | 5 |
| CRUISE31 | DB-P | Ranibizumab | Placebo | None | 392 | CRVO | 68 (20–91) | 169 (43.1) | 12 | 11.0 | 5 |
| DRCR32 | DB-P | Ranibizumab | Placebo, triamcinolone | Laser | 691 | DME | 63 (NA) | 304 (44.0) | 24 | 6.4 | 5 |
| RESTORE33 | DB-P | Ranibizumab | Placebo | Laser | 345 | DME | 63 (NA) | 144 (41.7) | 12 | 12.2 | 5 |
| Macugen 101334 | DB-P | Pegaptanib | Placebo | Laser | 260 | DME | 62 (20–83) | 111 (42.7) | 24 | 32.5 | 5 |
NA = data not available. DB-P = double blind parallel; SB-P = single blind parallel. AMD = age-related macular degeneration; DME = diabetic macular edema; CRVO = central retinal vein occlusion; BRVO = branch retinal vein occlusion.